Status:

COMPLETED

WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

Lead Sponsor:

Hoffmann-La Roche

Collaborating Sponsors:

Trimeris

Conditions:

HIV Infections

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The purpose of this study is to evaluate the tolerability of a subcutaneous needle-free injection device used to administer Fuzeon, compared with the standard needle/syringe supplied with commercial F...

Eligibility Criteria

Inclusion

  • male or female patients, \>=18 years of age with HIV-1 infection;
  • previously treated with antiretroviral agents.

Exclusion

  • prior use of Fuzeon or T-1249;
  • inability to self-inject;
  • active, untreated opportunistic infection.

Key Trial Info

Start Date :

August 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2006

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT00233883

Start Date

August 1 2005

End Date

July 1 2006

Last Update

November 3 2015

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

Long Beach, California, United States, 90813

2

Los Angeles, California, United States, 90022

3

Los Angeles, California, United States, 90036

4

Los Angeles, California, United States, 90210

WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. | DecenTrialz